Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 4
Submit an article Journal homepage
506
Views
6
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

MPN10 score and survival of molecularly annotated myeloproliferative neoplasm patients

Yasser H. ElNahassNational Cancer Institute, Cairo University, Cairo, Egypt; Correspondence[email protected]
,
Hossam K. MahmoudNational Cancer Institute, Cairo University, Cairo, Egypt;
,
Mervat M. MattarFaculty of Medicine, Cairo University, Cairo, Egypt;
,
Omar A. FahmyFaculty of Medicine, Cairo University, Cairo, Egypt;
,
Mohamed A. SamraNational Cancer Institute, Cairo University, Cairo, Egypt;
,
Raafat M. AbdelfattahNational Cancer Institute, Cairo University, Cairo, Egypt;
,
Fatma A. ElRefaeyNational Cancer Institute, Cairo University, Cairo, Egypt;
,
Hala M. FahmyFaculty of Medicine, Cairo University, Cairo, Egypt;
,
Gamal M. FathyNasser Institute of Health, Cairo, Egypt;
,
Ahmed AbdulgawadFaculty of Medicine, Cairo University, Cairo, Egypt;
,
Mohamed AbdelKaderFaculty of Medicine, Cairo University, Cairo, Egypt;
,
Hend N. ElleithyFaculty of Medicine, Cairo University, Cairo, Egypt;
,
Mona GamilFaculty of Medicine, Cairo University, Cairo, Egypt;
,
Mohamed TalaatFaculty of Medicine, Cairo University, Cairo, Egypt;
,
Heba A. NaderGenome Onco-Center, Cairo, Egypt
&
Wafaa H. ElMetnawyFaculty of Medicine, Cairo University, Cairo, Egypt;
show all
Pages 844-854 | Received 04 May 2017, Accepted 29 Jul 2017, Published online: 22 Aug 2017
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

JAK2, CALR, MPL and triple-negative mutational status has a direct impact on symptom severity and disease burden assessed by MPN10 score in myeloproliferative neoplasms (MPNs). Among 93 patients; median MPN10 score was 48 (5–76) in JAK2 mutants versus 25 (4–80) in JAK2 negative (p < .001); 22.5 (4–65) in CALR mutants versus 35 (5–80) in CALR negative (p < .050) and 21 (10–48) in triple negative versus 40 (4–80) in JAK2/CALR/MPL mutants (p < .001). At three years, progression free and overall survival of JAK2-positive versus JAK2-negative patients were 62% versus 100% (p < .001); 85% versus 100% (p = .011) and were 100% versus 78% (p = .067); 100% versus 92% (p = .197) in CALR-positive versus CALR-negative patients and 100% versus 75% (p = .004); 100% versus 90% (p = .015) in triple negative versus mutant patients, respectively. MPN10 score in association with driver gene mutations can be used as a predictor of survival in MPN patients.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1365852.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.